Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of esaxerenone in autosomal dominant polycystic kidney disease
jRCTs031260561Phase 2Recruiting
- Sponsor
- Chiba University Hospital
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esaxerenone in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Chiba University Hospital. Primary endpoint: Annual rate of decline in eGFRcr. Started Oct 2026; status: recruiting.
02
Drugs
esaxerenone
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCTs031260561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260561.